(+)-3-ethoxy-17-methylmorphinan | 99003-82-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (+)-3-ethoxy-17-methylmorphinan
• 英文别名: dextroethorphan；(1S,9S,10S)-4-ethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
• CAS: 99003-82-4
• 化学式: C₁₉H₂₇NO
• 分子量: 285.429
• InChiKey: DIWAJQNYTVAWMY-NEWSRXKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基三乙基氢氧化铵 、 alkaline earth salt of/the/ methylsulfuric acid 生成 (+)-3-ethoxy-17-methylmorphinan
  参考文献：
  名称：

  氧化吗啡烷。（3. Mitteilung）。光学活性3-氧吗啡烷

  摘要：

  光学显微镜中的3-Oxy-N-烷基-吗啡烷被烧成灰烬，而在ther和Esterübergeführt中则消失了。

  DOI：

  10.1002/hlca.19510340715

文献信息

• Morphinan compounds
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US10022370B2

  公开（公告）日：2018-07-17

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型吗啡南化合物及其药学上可接受的盐类。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗疾病和病症的方法中的用途，这些疾病和病症通过施用同时具有 NMDA 拮抗剂活性的 σ1 受体激动剂而得到有益的治疗。
• MORPHINAN COMPOUNDS
  申请人：Graham Philip B.

  公开号：US20110257214A1

  公开（公告）日：2011-10-20

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.
• COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
  申请人：Thomas Amanda

  公开号：US20120053169A1

  公开（公告）日：2012-03-01

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt of either of the foregoing and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.
• US8710072B2
  申请人：——

  公开号：US8710072B2

  公开（公告）日：2014-04-29
• [EN] COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY<br/>[FR] COMBINAISON DE COMPOSÉS DE MORPHINANE ET D'ANTIDÉPRESSEUR POUR LE TRAITEMENT DE L'AFFECT PSEUDOBULBAIRE, DES MALADIES NEUROLOGIQUES, DE LA DOULEUR INCURABLE ET CHRONIQUE ET DES LÉSIONS CÉRÉBRALES
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2010062690A1

  公开（公告）日：2010-06-03

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt of either of the foregoing and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.